RxDoctor Payments Data

Violet Gray

Family · Sun City Center, FLNPI 1659084689

Payments from drug & device makers

$9,180in general payments, 2019–2025

Across 368 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Gilead$486
  • Merck$465
  • Pfizer$429
  • AstraZeneca$400
  • Takeda Pharmaceuticals U.S.A., Inc.$346
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,55582%
  • Education$2623%
  • Other$1,36315%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis49$1,993
Gilead(2 entities)22$486
Merck21$465
Pfizer23$429
AstraZeneca(2 entities)19$400
Takeda Pharmaceuticals U.S.A., Inc.14$346
Incyte Corporation13$342
E.r. Squibb & Sons, L.L.C.16$329
Bristol Myers Squibb11$305
Daiichi Sankyo Inc.10$264
Seagen Inc.7$244
Astellas Pharma US Inc10$224
Eisai Inc.9$215
Johnson & Johnson9$204
Lilly USA, LLC8$202
GSK10$201
AbbVie8$168
Bayer8$154
Sobi, Inc6$125
Regeneron Healthcare Solutions, Inc.4$120
Array Biopharma Inc5$118
Taiho Oncology, Inc.5$115
Beigene USA, Inc.5$112
Genentech USA, Inc.6$111
Blueprint Medicines Corporation4$106
Stemline Therapeutics Inc.4$97
Tersera Therapeutics LLC3$84
Pharmacosmos Therapeutics Inc.4$72
EMD Serono, Inc.3$59
Sanofi2$56
Servier Pharmaceuticals LLC3$52
Rigel Pharmaceuticals, Inc.2$51
Exelixis Inc.3$50
Boehringer Ingelheim2$48
Pharmaessentia USA Corporation3$47
Adaptive Biotechnologies Corporation2$47
Genmab U.S., Inc.2$46
Morphosys, US Inc.2$42
Agios Pharmaceuticals, Inc.2$40
Amgen2$40
Foundation Medicine, Inc.2$39
Sumitomo Pharma America, Inc.2$35
Sun Pharmaceutical Industries Inc.1$34
Mirati Therapeutics, Inc.2$32
Kyowa Kirin, Inc.1$28
Argenx US, Inc.1$28
Dendreon Pharmaceuticals LLC1$27
Beone Medicines USA, Inc.1$26
Geron Corporation1$25
Acrotech Biopharma Inc.1$24
Exact Sciences1$24
Recordati_rare_diseases_inc.1$23
Apellis Pharmaceuticals, Inc.1$23
Ipsen Biopharmaceuticals, Inc1$23
Karyopharm Therapeutics Inc.1$22
Tolmar, Inc.1$21
Puma Biotechnology, Inc.1$20
AVEO Pharmaceuticals, Inc.1$19
Cumberland Pharmaceuticals, Inc.1$18
G1 Therapeutics, Inc.1$17

How this compares

$9,180 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$16,207
Anastrozole22$515
Letrozole19$353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$429$16,20713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Sun City Center

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →